AstraZeneca PLC (AZN) – “Rare diseases” a new disease area with the acquisition of Alexion

in Company Report, Healthcare & Life Sciences, Pharma & Biotech on October 13, 2021

AstraZeneca submitted preventive Covid 19 treatment for FDA Authorization. The company  aimed the antibody combination, called AZD7442 and delivered as a shot, at preventing Covid 19 symptoms, like a vaccine.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deal

 Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages : 38

Release Information

  • Released
    :

    October 13, 2021

  • Last Updated
    :

    February 24, 2022